- AS601245
-
- $41.00
-
2026-05-11
- CAS:345987-15-7
- Purity: 98.00%
- Supply Ability: 10g
|
| | AS601245 Basic information |
| Product Name: | AS601245 | | Synonyms: | 2-(1,3-benzothiazol-2-yl)-2-[2-(2-pyridin-3-ylethylamino)pyrimidin-4-yl]acetonitrile;AS601245;AS601245.TFA;JNK Inhibitor V;alpha-[2-[[2-(3-Pyridinyl)ethyl]amino]-4-pyrimidinyl]-2-benzothiazoleacetonitrile;CS-1619;2-Benzothiazoleacetonitrile, α-[2-[[2-(3-pyridinyl)ethyl]amino]-4-pyrimidinyl]-;2-(Benzo[d]thiazol-2-yl)-2-(2-((2-(pyridin-3-yl)ethyl)amino)pyrimidin-4-yl)acetonitrile | | CAS: | 345987-15-7 | | MF: | C20H16N6S | | MW: | 372.45 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 345987-15-7.mol |  |
| | AS601245 Chemical Properties |
| Boiling point | 635.6±65.0 °C(Predicted) | | density | 1.366±0.06 g/cm3(Predicted) | | storage temp. | Keep in dark place,Sealed in dry,Store in freezer, under -20°C | | solubility | insoluble in H2O; insoluble in EtOH; ≥14.25 mg/mL in DMSO | | pka | 5.32±0.10(Predicted) | | form | White to yellow solid. | | color | Light yellow to yellow | | InChI | 1S/C20H16N6S/c21-12-15(19-25-17-5-1-2-6-18(17)27-19)16-8-11-24-20(26-16)23-10-7-14-4-3-9-22-13-14/h1-6,8-9,11,13,15H,7,10H2,(H,23,24,26) | | InChIKey | RCYPVQCPYKNSTG-UHFFFAOYSA-N | | SMILES | [s]1c2c(nc1C(c3nc(ncc3)NCCc4cnccc4)C#N)cccc2 |
| WGK Germany | WGK 1 | | HS Code | 2922500090 | | Storage Class | 11 - Combustible Solids |
| | AS601245 Usage And Synthesis |
| Uses | JNK Inhibitor V is an anti-inflammatory JNK inhibitor with neuroprotective properties. JNK Inhibitor V and Clofibrate (C586910) synergistically inhibit proliferation, induce apoptosis and differentiation via differential modulation of gene expression profile in human colon cancer cells. | | Definition | ChEBI: 2-(1,3-benzothiazol-2-yl)-2-[2-[2-(3-pyridinyl)ethylamino]-4-pyrimidinyl]acetonitrile is a member of benzothiazoles. | | Biological Activity | recent evidence suggests activation of the c-jun nh2-terminal protein kinase (jnk) signal transduction pathway may play a role in ischemia-induced cell death. therefore, preventing the activation of jnk, or c-jun phosphorylation could be neuroprotective. as601245 is a c-jun nh2-terminal protein kinase inhibitor. | | in vitro | as601245 demonstrated a nonspecific inhibition of the three jnk human isoforms. as601245 inhibits isolated hjnk3 in an atpcompetitive manner. selectivity of as601245 was tested against a large panel of kinases. it exhibited 10- to 20-fold selectivity over c-src, cdk2, and c-raf and more than 50- to 100-fold selectivity over a range of tyr- and ser/thr-protein kinases [1]. | | in vivo | as601245 administered i.p. provided significant protection against the delayed loss of hippocampal ca1 neurons in a gerbil model of transient global ischemia. this effect is mediated by jnk inhibition and thus by c-jun expression and phosphorylation. a significant neuroprotective effect of as601245 administered either by i.p. injection or as i.v. bolus followed by an i.v. infusion was also observed in rats after focal cerebral ischemia [1]. | | IC 50 | 150, 220, and 70 nm for hjnk1, hjnk2, and hjnk3, respectively | | references | [1] carboni s, hiver a, szyndralewiez c, gaillard p, gotteland jp, vitte pa. as601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-jun nh2-terminal protein kinase inhibitor with neuroprotective properties. j pharmacol exp ther. 2004 jul;310(1):25-32. epub 2004 feb 26. |
| | AS601245 Preparation Products And Raw materials |
|